drugset
drugset / Trial / NCT06400511

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

NCT06400511 ↗

Phase 3 Terminated 477 enrolled Famy Life Sciences, a Viatris Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

Timeline

Start
2024-04-22
Primary completion
2025-09-09
Completion
2025-10-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pimecrolimus Small molecule 0.3 % Topical

Indications

blepharitis